• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Quantitative Insights wins FDA de novo nod for QuantX machine learning cancer diag

Quantitative Insights wins FDA de novo nod for QuantX machine learning cancer diag

July 28, 2017 By Fink Densford

Quantitative Insights

Quantitative Insights said yesterday it won FDA de novo clearance for its QuantX Advanced computer-aided diagnosis platform designed for evaluating breast abnormalities, touting it as the 1st such program to integrate machine learning.

The Chicago-based company said the software platform includes embedded tools, including its QI Score and Similar Case Database Compare, which provide similarity assessment against a “robust database of abnormalities with clinically documented pathology.”

QI said that the system has resulted in a new device Indication for Use through the FDA’s de novo pathway.

“QuantX provides valuable additional information for multi-modality breast imaging decision support. With a single click, we have access to advanced machine learning analytics showing how the abnormality being analyzed compares to similar abnormalities with known pathology. This impacts a radiologist’s confidence and improves reading time, and now we have clinical-study proof that it also significantly improves diagnostic performance,” QI medical advisor Dr. Gillian Newstead said in a press release.

The QuantX platform includes licensed technology from Maryellen Giger’s research labs at The Univeristy of Chicago, which QI said it has had a long-standing collaborative relationship with.

“Quantitative Insights has demonstrated that they can successfully take meaningful clinical innovations from research labs and clinics, develop them into products, take them through the regulatory process, and to the market,” QI scientific advisor Maryellen Giger of The University of Chicago said in a preapred statement.

The company said it is pursuing a product launch in the US, as well as distribution partners for the US and international markets.

“This clearance marks a true breakthrough in the diagnosis and management of cancers, starting with breast. In our FDA clinical study, QuantX was shown to improve the diagnostic performance of radiologists, enabling faster and more accurate diagnosis, more personalized treatments, and better outcomes for patients. With QuantX Advanced, we are now ‘all-in’ in the fight against breast cancer,” CEO Keith Tipton said in a prepared statement.

Filed Under: 510(k), Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Women's Health Tagged With: quantitativeinsights

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy